Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 5/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451679 | 0.86 | HDAC4 (0.41) | HDAC4AKR1C1HDAC9HSD11B1OPRM1 | |
| Benzene SCHEMBL28354853 | 0.86 | HDAC4 (0.41) | HDAC4AKR1C1HDAC9HSD11B1OPRM1 | |
| SCHEMBL3836530 | 0.83 | HDAC4 (0.39) | HDAC4AKR1C1HDAC9TSHRHSD11B1 | |
| SCHEMBL29120630 | 0.83 | HDAC4 (0.39) | HDAC4AKR1C1HDAC9HSD11B1OPRM1 | |
| SCHEMBL29531155 | 0.81 | HDAC4 (0.38) | HDAC4AKR1C1HDAC9POLBCYP3A4 | |
| SCHEMBL28878362 | 0.79 | HDAC4 (0.33) | HDAC4 | |
| SCHEMBL28916077 | 0.79 | HDAC4 (0.33) | HDAC4 | |
| SCHEMBL5232783 | 0.77 | HDAC4 (0.41) | HDAC4AKR1C1POLBCYP3A4PARP1 | |
| SCHEMBL14889498 | 0.76 | CES2 (0.36) | HDAC4MAPTCYP2C19RECQLL3MBTL1 | |
| Acetonitrile SCHEMBL28747283 | 0.76 | CYP11B1 (0.34) | HDAC4AKR1C1MAPTHSD17B10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968207-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI Foundation, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014159218-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-114671920-B | Amide pentaacetyl geniposide derivative as well as preparation method and application thereof | 山东省农业科学院 | 2023-06-20 | — | — | CN | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3065728-A1 | NOVEL METHODS | Aeromics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2968207-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI Foundation, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015069948-A1 | NOVEL METHODS | AEROMICS, LLC (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-2846787-A2 | NEW METHODS | Aeromics LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2014159218-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013169939-A2 | NEW METHODS | AEROMICS, LLC (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | HDAC4 748/4885AKR1C1 2091/4885HDAC9 2178/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | HDAC4 892/4885AKR1C1 2138/4885HDAC9 2145/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | HDAC4 937/4885AKR1C1 2485/4885HDAC9 2185/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | HDAC4 1027/4885AKR1C1 2503/4885HDAC9 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.